(SANA) Sana Biotechnology - Ratings and Ratios
Allogeneic Islet Therapy, CAR-T Oncology, Hypoimmune Platform, Fusosome Delivery
SANA EPS (Earnings per Share)
SANA Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 105% |
| Value at Risk 5%th | 149% |
| Relative Tail Risk | -13.88% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.84 |
| Alpha | 16.62 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.617 |
| Beta | 2.019 |
| Beta Downside | 1.295 |
| Drawdowns 3y | |
|---|---|
| Max DD | 88.11% |
| Mean DD | 45.88% |
| Median DD | 48.57% |
Description: SANA Sana Biotechnology October 23, 2025
Sana Biotechnology (NASDAQ:SANA) is a Seattle-based biotech firm that develops engineered-cell medicines for high-unmet-need areas such as type 1 diabetes, B-cell-mediated autoimmune disorders, and oncology, using both ex vivo and in vivo cell-engineering platforms.
Its current pipeline includes: UP421 (allogeneic HIP-modified islet cells, Phase 1 for type 1 diabetes); SC451 (stem-cell-derived islet cells, preclinical for type 1 diabetes); SC291 (HIP-modified CD19-directed allogeneic CAR-T, Phase 1 for systemic lupus erythematosus and ANCA-associated vasculitis, with additional preclinical autoimmune programs); SC262 (hypoimmune CD22-directed allogeneic CAR-T, Phase 1 for non-Hodgkin’s lymphoma); and SG299 (CD8-targeted fusosome, preclinical for hematologic malignancies and autoimmune disease). The company also holds a CRISPR-Cas12b licensing deal with Beam Therapeutics and an IP agreement with Harvard for hypoimmune cell technology.
From a market-level perspective, SANA’s market capitalization hovers around $1.2 billion, with a cash runway of roughly 12 months based on its latest 10-Q filing. The broader cell-therapy sector is projected to exceed $30 billion by 2030, driven by increasing FDA approvals and payer acceptance, while biotech R&D spend is growing at ~10 % YoY-both factors that could materially affect Sana’s financing and valuation dynamics.
If you’re looking to deepen your quantitative assessment, ValueRay’s platform offers a granular, data-driven view of Sana’s risk-adjusted upside that’s worth exploring further.
SANA Stock Overview
| Market Cap in USD | 975m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-02-04 |
| Return 12m vs S&P 500 | 34.4% |
| Analyst Rating | 4.38 of 5 |
SANA Dividends
Currently no dividends paidSANA Growth Ratios
| CAGR 3y | -5.76% |
| CAGR/Max DD Calmar Ratio | -0.07 |
| CAGR/Mean DD Pain Ratio | -0.13 |
| Current Volume | 4174.1k |
| Average Volume | 4391.8k |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-234.4m TTM) > 0 and > 6% of Revenue (6% = 916.9k TTM) |
| FCFTA -0.36 (>2.0%) and ΔFCFTA 12.68pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.36 (>3.0%) and CFO -158.3m > Net Income -234.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.55 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (260.5m) change vs 12m ago 10.65% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 3.07% (prev 0.0%; Δ 3.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.80 (EBITDA TTM -178.6m / Interest Expense TTM 40.4m) >= 6 (WARN >= 3) |
Altman Z'' -21.95
| (A) 0.29 = (Total Current Assets 161.8m - Total Current Liabilities 35.5m) / Total Assets 435.4m |
| (B) -4.11 = Retained Earnings (Balance) -1.79b / Total Assets 435.4m |
| warn (B) unusual magnitude: -4.11 — check mapping/units |
| (C) -0.39 = EBIT TTM -194.0m / Avg Total Assets 497.4m |
| (D) -7.46 = Book Value of Equity -1.79b / Total Liabilities 240.1m |
| Total Rating: -21.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.93
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -17.43% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.46 = 2.40 |
| 5. Debt/Ebitda 0.08 = 2.50 |
| 6. ROIC - WACC (= -91.34)% = -12.50 |
| 7. RoE -120.6% = -2.50 |
| 8. Rev. Trend 21.84% = 1.64 |
| 9. EPS Trend 38.06% = 1.90 |
What is the price of SANA shares?
Over the past week, the price has changed by -2.44%, over one month by -10.34%, over three months by +16.33% and over the past year by +54.05%.
Is Sana Biotechnology a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SANA is around 3.85 USD . This means that SANA is currently overvalued and has a potential downside of -3.51%.
Is SANA a buy, sell or hold?
- Strong Buy: 4
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SANA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.4 | 111.3% |
| Analysts Target Price | 8.4 | 111.3% |
| ValueRay Target Price | 4.4 | 11.3% |
SANA Fundamental Data Overview November 15, 2025
P/B = 5.5385
Beta = 1.95
Revenue TTM = 15.3m USD
EBIT TTM = -194.0m USD
EBITDA TTM = -178.6m USD
Long Term Debt = 82.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 14.8m USD (from shortTermDebt, last quarter)
Debt = 89.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -13.6m USD (from netDebt column, last quarter)
Enterprise Value = 911.6m USD (974.9m + Debt 89.7m - CCE 153.1m)
Interest Coverage Ratio = -4.80 (Ebit TTM -194.0m / Interest Expense TTM 40.4m)
FCF Yield = -17.43% (FCF TTM -158.8m / Enterprise Value 911.6m)
FCF Margin = -1039 % (FCF TTM -158.8m / Revenue TTM 15.3m)
Net Margin = -1534 % (Net Income TTM -234.4m / Revenue TTM 15.3m)
Gross Margin = 7.43% ((Revenue TTM 15.3m - Cost of Revenue TTM 14.1m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.09 (Enterprise Value 911.6m / Total Assets 435.4m)
Interest Expense / Debt = 2.15% (Interest Expense 1.93m / Debt 89.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -153.3m (EBIT -194.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.55 (Total Current Assets 161.8m / Total Current Liabilities 35.5m)
Debt / Equity = 0.46 (Debt 89.7m / totalStockholderEquity, last quarter 195.3m)
Debt / EBITDA = 0.08 (negative EBITDA) (Net Debt -13.6m / EBITDA -178.6m)
Debt / FCF = 0.09 (negative FCF - burning cash) (Net Debt -13.6m / FCF TTM -158.8m)
Total Stockholder Equity = 194.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -53.83% (Net Income -234.4m / Total Assets 435.4m)
RoE = -120.6% (Net Income TTM -234.4m / Total Stockholder Equity 194.4m)
RoCE = -70.14% (EBIT -194.0m / Capital Employed (Equity 194.4m + L.T.Debt 82.2m))
RoIC = -78.86% (negative operating profit) (NOPAT -153.3m / Invested Capital 194.4m)
WACC = 12.48% (E(974.9m)/V(1.06b) * Re(13.47%) + D(89.7m)/V(1.06b) * Rd(2.15%) * (1-Tc(0.21)))
Discount Rate = 13.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.90%
Fair Price DCF = unknown (Cash Flow -158.8m)
EPS Correlation: 38.06 | EPS CAGR: 27.50% | SUE: 0.20 | # QB: 0
Revenue Correlation: 21.84 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for SANA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle